Autologous CAR-T Cells Targeting B7-H3 in PDAC

The purpose of this gene therapy research study is to test the safety and tolerability of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen (iC9.CAR.B7-H3 T cells) in patients with pancreatic ductal adenocarcinoma that came back after receiving standard therapy for this cancer. The iC9.CAR.B7-H3 treatment is experimental and has not been approved by the Food and Drug Administration.

Trial Details

NCT ID
NCT06158139
Phase
PHASE1
Sponsor
UNC Lineberger Comprehensive Cancer Center
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • iC9-CAR.B7-H3 T cell infusion
Locations (sample)
  • Chapel Hill, North Carolina, United States|35.9132,-79.05584

Key Eligibility Criteria

  • Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for releasing personal health information ex…
  • Age ≥ 18 years at the time of consent.
  • Eastern Cooperative Oncology Group of 0-1 Performance Status)
  • Histological or cytological evidence/confirmation of pancreatic ductal adenocarcinoma.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →